Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1777-1783

  Riccobene, Todd A ^a   Rekeda, Ludmyla ^b   Rank, Douglas ^b   Llorens, Lily ^b  

^a FOREST RESEARCH INSTITUTE   (United States)

^b Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTAROLINE FOSAMIL; MOXIFLOXACIN; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; MALE; NEUTROPENIA; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AZA COMPOUNDS; CEPHALOSPORINS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; QUINOLINES; YOUNG ADULT;

EID: 84875167651     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02352-12     Document Type: Article

References (19)

1. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, Tomimoto M, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, Miyake A. 2003. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg. Med. Chem. 11: 2427-2437.
2. Ge Y, Biek D, Talbot GH, Sahm DF. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398 -3407.
3. Sader HS, Fritsche TR, Jones RN. 2008. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of communityacquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1153-1155.
4. Forest Pharmaceuticals, Inc. 2012. Teflaro (ceftaroline fosamil) prescribing information. Forest Pharmaceuticals, Inc., St. Louis, MO.
5. Ge Y, Redman R, Floren L, Liao S, Wikler M. 2006. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., poster A-1936.
6. Ge Y, Redman R, Floren L, Liao S, Wikler M. 2006. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., poster A-1937.
7. Ball P. 2000. Quinolone-induced QT interval prolongation: a not-sounexpected class effect. J. Antimicrob. Chemother. 45:557-559.
8. Roden DM. 2004. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350:1013-1022.
9. van Noord C, Eijgelsheim M, Stricker BHC. 2010. Drug-and non-drugassociated QT interval prolongation. Br. J. Clin. Pharmacol. 70:16 -23.
10. International Conference on Harmonization. October 2005. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. US Food and Drug Administration, Rockville, MD. http://www.fda.gov/RegulatoryInformation/Guidances/ucm129335.htm. Accessed 6 December 2011.
11. Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. 2002. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87(3):220 -228.
12. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA. 2008. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin. Pharmacol. Ther. 84:475-480.
13. Darpo B, Fossa AA, Couderc Zhou J-PM, Schreyer A, Ticktin M, Zapesochny A. 2011. Improving the precision of QT measurements. Cardiol. J. 18(4):401-410.
14. Yan LK, Zhang J, Ng MJ, Dang Q. 2010. Statistical characteristics of moxifloxacin-induced QTc effect. J. Biopharm. Stat. 20:497-507.
15. Corrado ML. 2010. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):iv67-iv71.
16. Cerexa, Inc. 2009. Integrated summary of safety: ceftaroline fosamil for injection. Cerexa, Inc., Forest Laboratories, Inc., Oakland, CA.
17. Rank DR, Friedland HD, Laudano JB. 2011. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):iii53-iii59.
18. Riccobene T, Fang E, Thye D. 2009. An open-label pharmacokinetic (PK), safety, and tolerability study of single intravenous (IV) doses of ceftaroline (CPT) in subjects with normal renal function or severe renal impairment. Abstr. 49th Intersci Conf. Antimicrob. Agents Chemother., poster A1-003.
19. Morganroth J. 2007. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin. Pharmacol. Ther. 81(1): 108 -113.